European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug
EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with early Alzheimer's disease, reversing its initial decision from four months ago.
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.
European watchdog partially approves new Alzheimer's drug
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment.
EU regulator reverses decision to block Alzheimer's drug lecanemab
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients. In July, the Amsterdam-based European Medicines Agency (EMA) denied recommending approval of the drug made by Eisai and Biogen because it considered the risks - especially bleeding and swelling in the brain - to be greater than the potential benefits in a broad population.
Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved
Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be approved.
ScienceAlert on MSN15h
Brain Autopsies Reveal a Potential New Culprit Behind Alzheimer's
University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...
Healthier Together: New Alzheimer’s disease warning signs to look out for
A breakthrough in the fight against Alzheimer’s disease may have been made in Seattle. Researchers at the Allen Institute ...
Nasal Spray Could Delay Alzheimer's by Years
An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...
'We are very hopeful' | New nasal spray could delay Alzheimer's by years, researchers say
Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
STAT1d
Mild Alzheimer’s patients won’t save Cassava Sciences
As we count down toward the December readout of Cassava Sciences’ simufilam Phase 3 clinical trial in Alzheimer’s disease, ...
Alzheimer's Disease Month - Helping Those Living with the Disease
November is National Alzheimer’s Disease Month, and it’s also Caretaker Month. These two things often go hand-in-hand, but ...
Medscape16h
Infection Plus Pollution Equals Increased Alzheimer’s Risk
The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...
Richmond1hOpinion
Commentary: How to fight the stigma of Alzheimer's and dementia
Having a loved one with Alzheimer’s is incredibly taxing, both emotionally and physically. It’s OK to ask for help.